Association between Artificial Sweetener-Aspartame Consumption and Colorectal Cancer Risk: Evidence-Based Strategies.

IF 2.5 3区医学 Q3 ONCOLOGY Oncology Pub Date : 2024-01-01 Epub Date: 2023-11-02 DOI:10.1159/000534812

Chenglou Zhu, Dandan Ji, Jichun Ma, Mingxu Da

{"title":"Association between Artificial Sweetener-Aspartame Consumption and Colorectal Cancer Risk: Evidence-Based Strategies.","authors":"Chenglou Zhu, Dandan Ji, Jichun Ma, Mingxu Da","doi":"10.1159/000534812","DOIUrl":null,"url":null,"abstract":"<p><p>In this study, clinical trials were generalized, summarized, and meta-analyzed to evaluate correlations between artificial sweeteners (ASs) and colorectal cancer (CRC). PubMed, Web of Science, Embase (Ovid platform), MEDLINE, and the Cochrane Library databases were searched from inception until July 24, 2023. The association between AS exposure and CRC incidence was assessed using odds ratios (ORs) and 95% confidence intervals (CIs). STATA software (version 12.0) was used to perform the meta-analysis. Ten studies (three case-control studies and seven cohort studies) involving 711,537 participants were identified. Results showed that the intake of ASs reduced the incidence of CRC (OR = 0.93, 95% CI = [0.87-0.99]) and was not significantly associated with mortality (OR = 0.93, 95% CI = [0.83-1.05]). Subgroup analyses showed that low doses of ASs were associated with lower CRC incidence (OR = 0.90, 95% CI = [0.83-0.99]), and medium/high doses were not associated with CRC incidence (OR = 1.11, 95% CI = [0.93-1.33]; OR = 0.89, 95% CI = [0.79-1.00], respectively). Moreover, low, medium, and high exposures were not associated with an increased risk of mortality due to CRC (OR = 0.95, 95% CI = [0.80-1.14]; OR = 0.99, 95% CI = [0.88-1.11]; OR = 0.93, 95% CI = [0.71-1.21], respectively). The results of our meta-analysis showed that a low intake of ASs may be associated with a lower risk of CRC.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000534812","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In this study, clinical trials were generalized, summarized, and meta-analyzed to evaluate correlations between artificial sweeteners (ASs) and colorectal cancer (CRC). PubMed, Web of Science, Embase (Ovid platform), MEDLINE, and the Cochrane Library databases were searched from inception until July 24, 2023. The association between AS exposure and CRC incidence was assessed using odds ratios (ORs) and 95% confidence intervals (CIs). STATA software (version 12.0) was used to perform the meta-analysis. Ten studies (three case-control studies and seven cohort studies) involving 711,537 participants were identified. Results showed that the intake of ASs reduced the incidence of CRC (OR = 0.93, 95% CI = [0.87-0.99]) and was not significantly associated with mortality (OR = 0.93, 95% CI = [0.83-1.05]). Subgroup analyses showed that low doses of ASs were associated with lower CRC incidence (OR = 0.90, 95% CI = [0.83-0.99]), and medium/high doses were not associated with CRC incidence (OR = 1.11, 95% CI = [0.93-1.33]; OR = 0.89, 95% CI = [0.79-1.00], respectively). Moreover, low, medium, and high exposures were not associated with an increased risk of mortality due to CRC (OR = 0.95, 95% CI = [0.80-1.14]; OR = 0.99, 95% CI = [0.88-1.11]; OR = 0.93, 95% CI = [0.71-1.21], respectively). The results of our meta-analysis showed that a low intake of ASs may be associated with a lower risk of CRC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

食用人造甜味剂与结直肠癌癌症风险之间的关系：循证策略。

在本研究中，对临床试验进行了概括、总结和荟萃分析，以评估人工甜味剂（AS）与癌症（CRC）之间的相关性。PubMed、Web of Science、EMBASE（Ovid平台）、MEDLINE和Cochrane图书馆数据库从成立到2023年7月24日进行了搜索。使用比值比（OR）和95%置信区间（CI）评估AS暴露与CRC发病率之间的相关性。使用STATA软件（12.0版）进行荟萃分析。确定了10项研究（3项病例对照研究和7项队列研究），涉及711537名参与者。结果显示，摄入ASs可降低CRC的发生率（OR=0.93，95%CI=[0.87-0.9]），与死亡率无显著相关性（OR=0.73，95%CI==0.83-1.05]）。亚组分析显示，低剂量ASs与较低的CRC发生率相关（OR=0.90，95%CI=[883-0.9]），和中/高剂量与CRC发病率无关（OR=1.11，95%CI=[0.93-1.33]；OR=0.89，95%CI=[779-1.00]）。此外，低、中、高暴露与CRC导致的死亡风险增加无关（OR=0.95，95%CI=[0.80-1.114]；OR=0.99，95%CI=[88-1.11]；OR=0.93，95%CI=[77-1.21]）。我们的荟萃分析结果表明，ASs摄入量低可能与CRC风险低有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.